The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
 
Michele Ly
No Relationships to Disclose
 
Daniela Molena
No Relationships to Disclose
 
Smita Sihag
No Relationships to Disclose
 
Abraham Jing-Ching Wu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; MORE Health; MORE Health; MORE Health; MORE Health
Research Funding - CivaTech Oncology; CivaTech Oncology; CivaTech Oncology; CivaTech Oncology
Travel, Accommodations, Expenses - Alpha Tau; Alpha Tau; Alpha Tau; Alpha Tau; CivaTech Oncology; CivaTech Oncology; CivaTech Oncology; CivaTech Oncology
 
Pari M. Shah
No Relationships to Disclose
 
Ping Gu
No Relationships to Disclose
 
Ryan Sugarman
No Relationships to Disclose
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences
Honoraria - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; MedEd; MedEd; MedEd; MedEd; RMEI Medical Education; RMEI Medical Education; RMEI Medical Education; RMEI Medical Education
Consulting or Advisory Role - Health Advances; Health Advances; Health Advances; Health Advances
Research Funding - Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
Sree Bhavani Chalasani
No Relationships to Disclose
 
Marina Shcherba
No Relationships to Disclose
 
Randy Yeh
No Relationships to Disclose
 
Laura H. Tang
No Relationships to Disclose
 
Carly Alterman
No Relationships to Disclose
 
Paige Collins
No Relationships to Disclose
 
Kendall Cowie
No Relationships to Disclose
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Rgenix; Rgenix; Rgenix; Rgenix
Research Funding - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Genentech; Genentech; Genentech; Genentech; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals
Research Funding - Arog (Inst); Arog (Inst); Arog (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Zymeworks; Zymeworks; Zymeworks; Zymeworks
Travel, Accommodations, Expenses - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals